Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Drugs in Pipeline
189
Phase 3 Programs
118
Upcoming Catalysts
12
Next Catalyst
Apr 17, 2026
12wStock performance and market intelligence
12 upcoming, 0 past
Primary completion for Risdiplam trial (NCT05808764) in Muscular Atrophy, Spinal
SourcePrimary completion for RO7795081 trial (NCT07081958) in Obesity or Overweight
SourcePrimary completion for Alectinib trial (NCT03194893) in Neoplasms
SourcePrimary completion for Crizotinib trial (NCT03194893) in Neoplasms
SourcePrimary completion for Inavolisib trial (NCT05646862) in Breast Cancer
SourcePrimary completion for Atezolizumab trial (NCT05047250) in Non-Small Cell Lung Cancer
SourcePrimary completion for ZN-A-1041 trial (NCT05593094) in Advanced Solid Tumors
SourcePrimary completion for RO7204239 trial (NCT06965413) in Obesity
SourcePrimary completion for RO7269162 trial (NCT06402838) in Alzheimer's Disease
SourcePrimary completion for Risdiplam trial (NCT05808764) in Muscular Atrophy, Spinal
SourcePrimary completion for Bevacizumab 15 mg/kg trial (NCT04524871) in Advanced Liver Cancers
SourcePrimary completion for Tocilizumab trial (NCT04524871) in Advanced Liver Cancers
SourceMachine learning insights and smart money movement
Pending NDA/BLA submissions with predicted PDUFA dates
Clinical development programs and drug candidates
RO7204239
Obesity
Vemurafenib
Melanoma
Ranibizumab
Diabetic Macular Edema
Emicizumab
Hemophilia A
Afimkibart
Crohns Disease
Docetaxel
Non-Small Cell Lung Cancer
tocilizumab [RoActemra/Actemra]
Rheumatoid Arthritis
Trastuzumab
Breast Cancer
Rituximab
Rheumatoid Arthritis
Atezolizumab
Carcinoma, Hepatocellular
aleglitazar
Diabetes Mellitus Type 2
Chemotherapy
Non-Small Cell Lung Cancer
Inavolisib
Breast Cancer
Baseline Treatment
Neuromyelitis Optica (NMO)
Acetaminophen/Paracetamol
Systemic Lupus Erythematosus
Phesgo
Locally Advanced or Metastatic Breast Cancer
Fludarabine Phosphate
Chronic Lymphocytic Leukemia
methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Anemia
Pemetrexed
Carcinoma, Non-Small-Cell Lung
Ortho-Novum® 1/35
Rheumatoid Arthritis
Cobimetinib
Melanoma
Crovalimab
Atypical Hemolytic Uremic Syndrome
Darbepoetin alfa
Anemia
Carboplatin
Breast Cancer
Etoposide
Small Cell Lung Carcinoma
Mycophenolate Mofetil
Pemphigus Vulgaris
Tiragolumab
Small Cell Lung Cancer
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Triple-Negative Breast Cancer
methylprednisolone
Rheumatoid Arthritis
epoetin alfa or beta
Anemia
Remdesivir
COVID-19 Pneumonia
Enfuvirtide
HIV Infections
chlorambucil
Lymphocytic Leukemia, Chronic
5-Fluoruracil
Gastric Cancer
Crizotinib
Neoplasms
Divarasib
Non-Small Cell Lung Cancer
Rituximab SC
Non-Hodgkin's Lymphoma
Permitted DMARDs
Rheumatoid Arthritis
Adalimumab
Ulcerative Colitis
temozolomide
Glioblastoma Multiforme
Lamivudine
HIV Infections
PDS Implant with Ranibizumab 100 mg/mL
Neovascular Age-Related Macular Degeneration
Erlotinib
Non-Squamous Non-Small Cell Lung Cancer
satralizumab
Neuromyelitis Optica Spectrum Disorder
MMF
Lupus Nephritis
interferon-a-2a
Lymphoma
Baloxavir Marboxil
Influenza
TRO19622
Amyotrophic Lateral Sclerosis
XELOX
Colorectal Cancer
Standard adjuvant chemotherapy
Breast Cancer
DMARD
Rheumatoid Arthritis
Mycophenolate Mofetil 2 g/Day
Pemphigus Vulgaris (PV)
Lebrikizumab
Asthma
Faricimab
Wet Macular Degeneration
Pegylated-interferon Alfa-2a
Hepatitis C, Chronic
fusidic acid [Verutex]
Non-Small Cell Lung Cancer
Risdiplam
Muscular Atrophy, Spinal
Ocrelizumab
Multiple Sclerosis
Pegylated Interferon (PEG-IFN) alfa-2a
Hepatitis D, Chronic
Enzalutamide
Prostatic Neoplasms, Castration-Resistant
oseltamivir
Influenza, Human
Gemcitabine (Chemotherapy)
Ovarian Cancer
Second-Line Chemotherapy
Non-Squamous Non-Small Cell Lung Cancer
Nelfinavir mesylate
HIV Infections
Zalcitabine
HIV Infections
Efavirenz
HIV Infections
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Etrozulimab
Ulcerative Colitis
Vinflunine
Bladder Cancer
Astegolimab
Chronic Obstructive Pulmonary Disease (COPD)
Vinorelbine
Non-Small Cell Lung Cancer
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Squamous Non-Small Cell Lung Cancer
Mycophenolate mofetil (MMF)
Lupus Nephritis
5-Fluorouracil
Gastric Cancer
Bendamustine
Chronic Lymphocytic Leukemia
Platinum chemotherapy (cisplatin or carboplatin)
Non-Squamous Non-Small Cell Lung Cancer
Irinotecan
Colorectal Cancer
Pertuzumab IV
Early Breast Cancer
Venetoclax
Chronic Lymphocytic Leukemia
RO7234292 (RG6042)
Huntington Disease
Epirubicin
Breast Cancer
erlotinib [Tarceva]
Non-Small Cell Lung Cancer
Saquinavir
HIV Infections
Obinutuzumab
Chronic Lymphocytic Leukemia (CLL)
rituximab [MabThera/Rituxan]
Rheumatoid Arthritis
Cyclophosphamide
Breast Cancer
liposomal doxorubicin
Ovarian Cancer
Omalizumab
Nasal Polyps
csDMARDs
Rheumatoid Arthritis
pertuzumab [Perjeta]
Breast Cancer
tocilizumab
Rheumatoid Arthritis
bevacizumab [Avastin]
Non-Squamous Non-Small Cell Lung Cancer
Etrolizumab
Crohn Disease
leucovorin
Colorectal Cancer
Epoetin beta
Anemia
Lurbinectedin
Small-Cell Lung Cancer
taspoglutide
Diabetes Mellitus Type 2
Bevacizumab
Carcinoma, Hepatocellular
Ibandronate
Post-Menopausal Osteoporosis
methotrexate
Rheumatoid Arthritis
peginterferon alfa-2a [Pegasys]
Hepatitis B, Chronic
Methoxy Polyethylene Glycol-Epoetin Beta
Anemia
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Carcinoma, Non-Squamous Non-Small Cell Lung
Capecitabine
Gastric Cancer
methoxy polyethylene glycol-epoetin beta [Mircera]
Anemia
Herceptin
Breast Cancer
Trastuzumab Emtansine
Breast Cancer
Gemcitabine
Pancreatic Cancer
Dexamethasone
Idiopathic Thrombocytopenic Purpura
Glofitamab
Diffuse Large B-cell Lymphoma
Alectinib
Non-Small Cell Lung Cancer
Cladribine
Lymphocytic Leukemia, Chronic
metformin
Diabetes Mellitus Type 2
ibandronate [Bonviva/Boniva]
Post-Menopausal Osteopenia
Trontinemab
Alzheimers Disease
Aflibercept
Diabetic Macular Edema
Paclitaxel
Ovarian Cancer
Sitagliptin
Diabetes Mellitus Type 2
Mircera
Anemia
Sunitinib
Renal Cell Carcinoma
Mosunetuzumab (IV)
B-cell Non-Hodgkin Lymphoma
RO4995819
Major Depressive Disorder
RO5217790
Cervical Intraepithelial Neoplasia
Actos
Diabetes Mellitus Type 2
PEGASYS
Hepatitis C, Chronic
Cisplatin
Nasopharyngeal Cancer
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
Metastatic Breast Cancer
5-FU
Colorectal Cancer
GK Activator (2)
Diabetes Mellitus Type 2
RO6889450
Schizophrenia, Schizoaffective Disorder
TRO40303
Acute Myocardial Infarctus
Basmisanil
Schizophrenia
ritonavir
HIV Infections
fluorouracil (5FU)
Colorectal Cancer
RG7774
Diabetic Retinopathy
PRM-151
Idiopathic Pulmonary Fibrosis
bitopertin [RO4917838]
Schizophrenia
dalcetrapib
Coronary Heart Disease
Standard chemotherapy
Breast Cancer
Entrectinib
Solid Tumors
First line chemotherapy
Mantle Cell Lymphoma
Zidovudine
HIV Infections
Cevostamab
Multiple Myeloma
Doxycline
Non-Small Cell Lung Cancer
Onartuzumab
Glioblastoma
Pirfenidone
Lung Diseases, Interstitial
Pertuzumab
Breast Cancer
GC33
Carcinoma, Hepatocellular
Rituximab IV
Lymphoma, Large B-Cell, Diffuse
RO4917523 0.5 mg
Fragile X Syndrome
Fenebrutinib
Relapsing Multiple Sclerosis
ANA598
HCV Infection
Copegus
Hepatitis C, Chronic
N-acetylcysteine
Idiopathic Pulmonary Fibrosis
OpRegen
Age-Related Macular Degeneration
Bevacizumab 15 mg/kg
Advanced Liver Cancers
TCS Cream
Atopic Dermatitis
RO7795081
Obesity or Overweight
RO5185426
Malignant Melanoma
RO7269162
Alzheimer's Disease
Englumafusp alfa
Lymphoma, Non-Hodgkin
P38 Inhibitor (4) 150mg
Rheumatoid Arthritis
Peginterferon alfa-2a
Carcinoma, Hepatocellular
capecitabine [Xeloda]
Colorectal Cancer
vismodegib
Basal Cell Carcinoma
Investigator's choice of anti-cancer treatment (except immunotherapy)
Breast Cancer
ZN-A-1041
Advanced Solid Tumors
fotemustine
Glioblastoma Multiforme
RO7490677
Primary Myelofibrosis
Anastrozole
Early Breast Cancer
Lomustine
Glioblastoma
Taxane (docetaxel or paclitaxel)
Breast Cancer
Temozolomide (TMZ)
High Grade Glioma
Sildenafil
Idiopathic Pulmonary Fibrosis
Olesoxime (TRO19622)
Chemotherapy-Induced Peripheral Neuropathy
5-Fluorouracil (5-FU)
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
RO4917523
Fragile X Syndrome
Erlotinib, escalating dose
Pancreatic Cancer
Epidoxorubicin
Breast Cancer
RG3421 120mg
Psoriasis
Oxaliplatin
Colorectal Cancer
RO7126209
Alzheimers Disease
Ribociclib
Breast Cancer
Metronidazole Actavis
Non-Squamous Non-Small Cell Lung Cancer
Vamikibart
Diabetic Macular Edema
Ocrelizumab Test Formulation
Multiple Sclerosis
Xeloda
Breast Cancer
C.E.R.A.
Anemia
cetuximab
Multiple Myeloma, Neoplasms
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
RO7204239 | Phase 3 | Obesity | - |
Vemurafenib | Phase 3 | Melanoma | - |
Ranibizumab | Phase 3 | Diabetic Macular Edema | - |
Emicizumab | Phase 3 | Hemophilia A | - |
Afimkibart | Phase 3 | Crohns Disease | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - |
tocilizumab [RoActemra/Actemra] | Phase 3 | Rheumatoid Arthritis | - |
Trastuzumab | Phase 3 | Breast Cancer | - |
Rituximab | Phase 3 | Rheumatoid Arthritis | - |
Atezolizumab | Phase 3 | Carcinoma, Hepatocellular | - |
aleglitazar | Phase 3 | Diabetes Mellitus Type 2 | - |
Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer | - |
Inavolisib | Phase 3 | Breast Cancer | - |
Baseline Treatment | Phase 3 | Neuromyelitis Optica (NMO) | - |
Acetaminophen/Paracetamol | Phase 3 | Systemic Lupus Erythematosus | - |
Phesgo | Phase 3 | Locally Advanced or Metastatic Breast Cancer | - |
Fludarabine Phosphate | Phase 3 | Chronic Lymphocytic Leukemia | - |
methoxy polyethylene glycol-epoetin beta [C.E.R.A.] | Phase 3 | Anemia | - |
Pemetrexed | Phase 3 | Carcinoma, Non-Small-Cell Lung | - |
Ortho-Novum® 1/35 | Phase 3 | Rheumatoid Arthritis | - |
Cobimetinib | Phase 3 | Melanoma | - |
Crovalimab | Phase 3 | Atypical Hemolytic Uremic Syndrome | - |
Darbepoetin alfa | Phase 3 | Anemia | - |
Carboplatin | Phase 3 | Breast Cancer | - |
Etoposide | Phase 3 | Small Cell Lung Carcinoma | - |
Mycophenolate Mofetil | Phase 3 | Pemphigus Vulgaris | - |
Tiragolumab | Phase 3 | Small Cell Lung Cancer | - |
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody | Phase 3 | Triple-Negative Breast Cancer | - |
methylprednisolone | Phase 3 | Rheumatoid Arthritis | - |
epoetin alfa or beta | Phase 3 | Anemia | - |
Remdesivir | Phase 3 | COVID-19 Pneumonia | - |
Enfuvirtide | Phase 3 | HIV Infections | - |
chlorambucil | Phase 3 | Lymphocytic Leukemia, Chronic | - |
5-Fluoruracil | Phase 3 | Gastric Cancer | - |
Crizotinib | Phase 3 | Neoplasms | - |
Divarasib | Phase 3 | Non-Small Cell Lung Cancer | - |
Rituximab SC | Phase 3 | Non-Hodgkin's Lymphoma | - |
Permitted DMARDs | Phase 3 | Rheumatoid Arthritis | - |
Adalimumab | Phase 3 | Ulcerative Colitis | - |
temozolomide | Phase 3 | Glioblastoma Multiforme | - |
Lamivudine | Phase 3 | HIV Infections | - |
PDS Implant with Ranibizumab 100 mg/mL | Phase 3 | Neovascular Age-Related Macular Degeneration | - |
Erlotinib | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - |
satralizumab | Phase 3 | Neuromyelitis Optica Spectrum Disorder | - |
MMF | Phase 3 | Lupus Nephritis | - |
interferon-a-2a | Phase 3 | Lymphoma | - |
Baloxavir Marboxil | Phase 3 | Influenza | - |
TRO19622 | Phase 3 | Amyotrophic Lateral Sclerosis | - |
XELOX | Phase 3 | Colorectal Cancer | - |
Standard adjuvant chemotherapy | Phase 3 | Breast Cancer | - |
DMARD | Phase 3 | Rheumatoid Arthritis | - |
Mycophenolate Mofetil 2 g/Day | Phase 3 | Pemphigus Vulgaris (PV) | - |
Lebrikizumab | Phase 3 | Asthma | - |
Faricimab | Phase 3 | Wet Macular Degeneration | - |
Pegylated-interferon Alfa-2a | Phase 3 | Hepatitis C, Chronic | - |
fusidic acid [Verutex] | Phase 3 | Non-Small Cell Lung Cancer | - |
Risdiplam | Phase 3 | Muscular Atrophy, Spinal | - |
Ocrelizumab | Phase 3 | Multiple Sclerosis | - |
Pegylated Interferon (PEG-IFN) alfa-2a | Phase 3 | Hepatitis D, Chronic | - |
Enzalutamide | Phase 3 | Prostatic Neoplasms, Castration-Resistant | - |
oseltamivir | Phase 3 | Influenza, Human | - |
Gemcitabine (Chemotherapy) | Phase 3 | Ovarian Cancer | - |
Second-Line Chemotherapy | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - |
Zalcitabine | Phase 3 | HIV Infections | - |
Efavirenz | Phase 3 | HIV Infections | - |
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | - |
Etrozulimab | Phase 3 | Ulcerative Colitis | - |
Vinflunine | Phase 3 | Bladder Cancer | - |
Astegolimab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - |
Vinorelbine | Phase 3 | Non-Small Cell Lung Cancer | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody | Phase 3 | Squamous Non-Small Cell Lung Cancer | - |
Mycophenolate mofetil (MMF) | Phase 3 | Lupus Nephritis | - |
5-Fluorouracil | Phase 3 | Gastric Cancer | - |
Bendamustine | Phase 3 | Chronic Lymphocytic Leukemia | - |
Platinum chemotherapy (cisplatin or carboplatin) | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - |
Irinotecan | Phase 3 | Colorectal Cancer | - |
Pertuzumab IV | Phase 3 | Early Breast Cancer | - |
Venetoclax | Phase 3 | Chronic Lymphocytic Leukemia | - |
RO7234292 (RG6042) | Phase 3 | Huntington Disease | - |
Epirubicin | Phase 3 | Breast Cancer | - |
erlotinib [Tarceva] | Phase 3 | Non-Small Cell Lung Cancer | - |
Saquinavir | Phase 3 | HIV Infections | - |
Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - |
rituximab [MabThera/Rituxan] | Phase 3 | Rheumatoid Arthritis | - |
Cyclophosphamide | Phase 3 | Breast Cancer | - |
liposomal doxorubicin | Phase 3 | Ovarian Cancer | - |
Omalizumab | Phase 3 | Nasal Polyps | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - |
pertuzumab [Perjeta] | Phase 3 | Breast Cancer | - |
tocilizumab | Phase 3 | Rheumatoid Arthritis | - |
bevacizumab [Avastin] | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - |
Etrolizumab | Phase 3 | Crohn Disease | - |
leucovorin | Phase 3 | Colorectal Cancer | - |
Epoetin beta | Phase 3 | Anemia | - |
Lurbinectedin | Phase 3 | Small-Cell Lung Cancer | - |
taspoglutide | Phase 3 | Diabetes Mellitus Type 2 | - |
Bevacizumab | Phase 3 | Carcinoma, Hepatocellular | - |
Ibandronate | Phase 3 | Post-Menopausal Osteoporosis | - |
methotrexate | Phase 3 | Rheumatoid Arthritis | - |
peginterferon alfa-2a [Pegasys] | Phase 3 | Hepatitis B, Chronic | - |
Methoxy Polyethylene Glycol-Epoetin Beta | Phase 3 | Anemia | - |
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Phase 3 | Carcinoma, Non-Squamous Non-Small Cell Lung | - |
Capecitabine | Phase 3 | Gastric Cancer | - |
methoxy polyethylene glycol-epoetin beta [Mircera] | Phase 3 | Anemia | - |
Herceptin | Phase 3 | Breast Cancer | - |
Trastuzumab Emtansine | Phase 3 | Breast Cancer | - |
Gemcitabine | Phase 3 | Pancreatic Cancer | - |
Dexamethasone | Phase 3 | Idiopathic Thrombocytopenic Purpura | - |
Glofitamab | Phase 3 | Diffuse Large B-cell Lymphoma | - |
Alectinib | Phase 3 | Non-Small Cell Lung Cancer | - |
Cladribine | Phase 3 | Lymphocytic Leukemia, Chronic | - |
metformin | Phase 3 | Diabetes Mellitus Type 2 | - |
ibandronate [Bonviva/Boniva] | Phase 3 | Post-Menopausal Osteopenia | - |
Trontinemab | Phase 3 | Alzheimers Disease | - |
Aflibercept | Phase 3 | Diabetic Macular Edema | - |
Paclitaxel | Phase 3 | Ovarian Cancer | - |
Sitagliptin | Phase 3 | Diabetes Mellitus Type 2 | - |
Mircera | Phase 2 | Anemia | - |
Sunitinib | Phase 2 | Renal Cell Carcinoma | - |
Mosunetuzumab (IV) | Phase 2 | B-cell Non-Hodgkin Lymphoma | - |
RO4995819 | Phase 2 | Major Depressive Disorder | - |
RO5217790 | Phase 2 | Cervical Intraepithelial Neoplasia | - |
Actos | Phase 2 | Diabetes Mellitus Type 2 | - |
PEGASYS | Phase 2 | Hepatitis C, Chronic | - |
Cisplatin | Phase 2 | Nasopharyngeal Cancer | - |
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg | Phase 2 | Metastatic Breast Cancer | - |
5-FU | Phase 2 | Colorectal Cancer | - |
GK Activator (2) | Phase 2 | Diabetes Mellitus Type 2 | - |
RO6889450 | Phase 2 | Schizophrenia, Schizoaffective Disorder | - |
TRO40303 | Phase 2 | Acute Myocardial Infarctus | - |
Basmisanil | Phase 2 | Schizophrenia | - |
ritonavir | Phase 2 | HIV Infections | - |
fluorouracil (5FU) | Phase 2 | Colorectal Cancer | - |
RG7774 | Phase 2 | Diabetic Retinopathy | - |
PRM-151 | Phase 2 | Idiopathic Pulmonary Fibrosis | - |
bitopertin [RO4917838] | Phase 2 | Schizophrenia | - |
dalcetrapib | Phase 2 | Coronary Heart Disease | - |
Standard chemotherapy | Phase 2 | Breast Cancer | - |
Entrectinib | Phase 2 | Solid Tumors | - |
First line chemotherapy | Phase 2 | Mantle Cell Lymphoma | - |
Zidovudine | Phase 2 | HIV Infections | - |
Cevostamab | Phase 2 | Multiple Myeloma | - |
Doxycline | Phase 2 | Non-Small Cell Lung Cancer | - |
Onartuzumab | Phase 2 | Glioblastoma | - |
Pirfenidone | Phase 2 | Lung Diseases, Interstitial | - |
Pertuzumab | Phase 2 | Breast Cancer | - |
GC33 | Phase 2 | Carcinoma, Hepatocellular | - |
Rituximab IV | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - |
RO4917523 0.5 mg | Phase 2 | Fragile X Syndrome | - |
Fenebrutinib | Phase 2 | Relapsing Multiple Sclerosis | - |
ANA598 | Phase 2 | HCV Infection | - |
Copegus | Phase 2 | Hepatitis C, Chronic | - |
N-acetylcysteine | Phase 2 | Idiopathic Pulmonary Fibrosis | - |
OpRegen | Phase 2 | Age-Related Macular Degeneration | - |
Bevacizumab 15 mg/kg | Phase 2 | Advanced Liver Cancers | - |
TCS Cream | Phase 2 | Atopic Dermatitis | - |
RO7795081 | Phase 2 | Obesity or Overweight | - |
RO5185426 | Phase 2 | Malignant Melanoma | - |
RO7269162 | Phase 2 | Alzheimer's Disease | - |
Englumafusp alfa | Phase 2 | Lymphoma, Non-Hodgkin | - |
P38 Inhibitor (4) 150mg | Phase 2 | Rheumatoid Arthritis | - |
Peginterferon alfa-2a | Phase 2 | Carcinoma, Hepatocellular | - |
capecitabine [Xeloda] | Phase 2 | Colorectal Cancer | - |
vismodegib | Phase 2 | Basal Cell Carcinoma | - |
Investigator's choice of anti-cancer treatment (except immunotherapy) | Phase 2 | Breast Cancer | - |
ZN-A-1041 | Phase 2 | Advanced Solid Tumors | - |
fotemustine | Phase 2 | Glioblastoma Multiforme | - |
RO7490677 | Phase 2 | Primary Myelofibrosis | - |
Anastrozole | Phase 2 | Early Breast Cancer | - |
Lomustine | Phase 2 | Glioblastoma | - |
Taxane (docetaxel or paclitaxel) | Phase 2 | Breast Cancer | - |
Temozolomide (TMZ) | Phase 2 | High Grade Glioma | - |
Sildenafil | Phase 2 | Idiopathic Pulmonary Fibrosis | - |
Olesoxime (TRO19622) | Phase 2 | Chemotherapy-Induced Peripheral Neuropathy | - |
5-Fluorouracil (5-FU) | Phase 2 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | - |
RO4917523 | Phase 2 | Fragile X Syndrome | - |
Erlotinib, escalating dose | Phase 2 | Pancreatic Cancer | - |
Epidoxorubicin | Phase 2 | Breast Cancer | - |
RG3421 120mg | Phase 2 | Psoriasis | - |
Oxaliplatin | Phase 2 | Colorectal Cancer | - |
RO7126209 | Phase 2 | Alzheimers Disease | - |
Ribociclib | Phase 2 | Breast Cancer | - |
Metronidazole Actavis | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - |
Vamikibart | Phase 2 | Diabetic Macular Edema | - |
Ocrelizumab Test Formulation | Phase 2 | Multiple Sclerosis | - |
Xeloda | Phase 2 | Breast Cancer | - |
C.E.R.A. | Phase 2 | Anemia | - |
cetuximab | Phase 2 | Multiple Myeloma, Neoplasms | - |
Approvals, filings, and latest developments